Literature DB >> 1757123

Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis.

J A Green1, G M Smith, R Buchta, R Lee, K Y Ho, I A Rajkovic, K F Scott.   

Abstract

Elevation of circulating phospholipase A2 (PLA2) activity is associated with sepsis and septic shock. Elevated levels of PLA2 activity also are seen in association with chronic inflammatory disorders such as rheumatoid arthritis. The relationship between these phospholipases is unclear. We have developed a highly specific enzyme-linked immunosorbent assay (ELISA) capable of measuring human synovial PLA2 in plasma, using monoclonal antibodies raised to recombinant synovial PLA2. This ELISA has been used to quantitate circulating PLA2 levels in patients clinically diagnosed with sepsis. These elevated levels positively correlated with the elevation seen in plasma PLA2 enzyme activity. The antibodies also have been used to purify immunoreactive PLA2 from plasma of patients with sepsis, thus enabling characterization of the purified protein by amino-terminal sequence analysis. We conclude from this study that the increase in PLA2 activity seen in association with sepsis and septic shock results from a dramatic elevation in levels of a circulating PLA2 enzyme. This inflammatory PLA2 is indistinguishable, both immunologically and chemically, from that associated with rheumatoid arthritis. Therapeutic agents directed towards inhibition of this inflammatory PLA2 enzyme may have utility in the treatment of both chronic and acute inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1757123     DOI: 10.1007/bf00917352

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  44 in total

Review 1.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

2.  Septic shock. Hemodynamics and pathogenesis.

Authors:  M M Parker; J E Parrillo
Journal:  JAMA       Date:  1983 Dec 23-30       Impact factor: 56.272

3.  Pancreatic phospholipase A2: isolation of the human gene and cDNAs from porcine pancreas and human lung.

Authors:  J J Seilhamer; T L Randall; M Yamanaka; L K Johnson
Journal:  DNA       Date:  1986-12

Review 4.  Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients.

Authors:  B E Kreger; D E Craven; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

5.  Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock.

Authors:  P Vadas; J B Hay
Journal:  Can J Physiol Pharmacol       Date:  1983-06       Impact factor: 2.273

6.  Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock.

Authors:  P Vadas
Journal:  J Lab Clin Med       Date:  1984-12

7.  Structure and properties of a human non-pancreatic phospholipase A2.

Authors:  R M Kramer; C Hession; B Johansen; G Hayes; P McGray; E P Chow; R Tizard; R B Pepinsky
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

8.  The risk factors, incidence, and prognosis of ARDS following septicemia.

Authors:  A M Fein; M Lippmann; H Holtzman; A Eliraz; S K Goldberg
Journal:  Chest       Date:  1983-01       Impact factor: 9.410

9.  Distributions of cardiopulmonary variables in pediatric survivors and nonsurvivors of septic shock.

Authors:  M M Pollack; A I Fields; U E Ruttimann
Journal:  Crit Care Med       Date:  1985-06       Impact factor: 7.598

10.  Incidence and outcome of the respiratory distress syndrome in gram-negative sepsis.

Authors:  R L Kaplan; S A Sahn; T L Petty
Journal:  Arch Intern Med       Date:  1979-08
View more
  38 in total

1.  Pathophysiological role of secretory type I and II phospholipase A2 in acute pancreatitis: an experimental study in rats.

Authors:  W Uhl; H J Schrag; N Schmitter; T J Nevalainen; J Aufenanger; A M Wheatley; M W Büchler
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluids.

Authors:  W Pruzanski; K Scott; G Smith; I Rajkovic; E Stefanski; P Vadas
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

3.  PLA2-responsive and SPIO-loaded phospholipid micelles.

Authors:  Qiang Gao; Lesan Yan; Michael Chiorazzo; E James Delikatny; Andrew Tsourkas; Zhiliang Cheng
Journal:  Chem Commun (Camb)       Date:  2015-08-07       Impact factor: 6.222

4.  Molecular basis of phospholipase A2 activity toward phospholipids with sn-1 substitutions.

Authors:  Lars Linderoth; Thomas L Andresen; Kent Jørgensen; Robert Madsen; Günther H Peters
Journal:  Biophys J       Date:  2007-09-07       Impact factor: 4.033

Review 5.  Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.

Authors:  W Lee Titsworth; Nai-Kui Liu; Xiao-Ming Xu
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

6.  Pancreatic and synovial type phospholipases A2 in serum samples from patients with severe acute pancreatitis.

Authors:  T J Nevalainen; J M Grönroos; P T Kortesuo
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

7.  Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synovium.

Authors:  O S Jamal; P G Conaghan; A M Cunningham; P M Brooks; V F Munro; K F Scott
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

8.  Are events after endotoxemia related to circulating phospholipase A2?

Authors:  A A Santos; J L Browning; M R Scheltinga; E A Lynch; E F Brown; P Lawton; E Chambers; I Dougas; C D Benjamin; C A Dinarello
Journal:  Ann Surg       Date:  1994-02       Impact factor: 12.969

9.  Genistein, a potent inhibitor of secretory phospholipase A2: a new insight in down regulation of inflammation.

Authors:  Kattepura K Dharmappa; Riyaz Mohamed; Holenarasipura V Shivaprasad; Bannikuppe Sannanaik Vishwanath
Journal:  Inflammopharmacology       Date:  2009-11-06       Impact factor: 4.473

10.  Hyperphospholipasemia A2 in human volunteers challenged with intravenous endotoxin.

Authors:  W Pruzanski; D W Wilmore; A Suffredini; G D Martich; A G Hoffman; J L Browning; E Stefanski; B Sternby; P Vadas
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.